Dramatically condensing radiation treatment for early prostate cancer into just 5 fractions produces good results without much toxicity, an early-phase study suggested. The hypofractionated schedule resulted in 99% biochemical and pathological control and only 1% experienced mild radiation side effects at 3 years, D. Andrew Loblaw, MD, of Sunnybrook Health Sciences Center in Toronto, and colleagues found.
Acute toxicity topped out at 1 case of grade 3 genitourinary problems among 83 patients treated, they reported here at the Genitourinary Cancers Symposium.
"That's a huge deal. Normal dosing is 40 to 45 fractions," Nicholas J. Vogelzang, MD, medical director of the developmental therapeutics committee of US Oncology, told MedPage Today. "Using accelerated hypofractionation, you can get what appear to be identical outcomes."
Not only would the once-weekly schedule with a total of only 5 radiation treatments used in the study be more convenient for patients, but it would likely substantially drop overall radiation costs, Vogelzang predicted.
Read more at: http://www.medpagetoday.com/MeetingCoverage/MGUCS/31020
Source: MedPage Today
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More